FDC Intraday Analysis...

FDC Share Price

Open 223.85 Change Price %
High 226.00 1 Day 1.55 0.70
Low 220.85 1 Week 4.55 2.08
Close 223.00 1 Month 9.85 4.62
Volume 159261 1 Year 0.05 0.02
52 Week High 244.00
52 Week Low 165.00
FDC Important Levels
Resistance 2 227.77
Resistance 1 225.81
Pivot 223.28
Support 1 220.19
Support 2 218.23
NSE INDIA Most Active Stocks
IFCI 27.25 16.45%
VISESHINFO 0.40 0.00%
SAIL 55.25 3.17%
SBIN 266.65 2.60%
ICICIBANK 268.45 2.17%
JINDALSTEL 74.20 1.50%
TANLA 59.75 19.98%
HCL-INSYS 61.30 1.07%
SUZLON 14.75 -1.01%
VEDL 245.45 1.03%
More..
NSE INDIA Top Gainers Stocks
VKSPL 0.15 50.00%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
SFL 1032.00 41.37%
RASOYPR 0.20 33.33%
PARASPETRO 0.25 25.00%
VIMALOIL 43.20 20.00%
ATNINTER 0.30 20.00%
EUROTEXIND 33.60 20.00%
TANLA 59.75 19.98%
More..
NSE INDIA Top Losers Stocks
INDIANHUME 400.40 -51.39%
SPYL 1.75 -18.60%
SURANAIND 3.85 -15.38%
GLOBOFFS 94.85 -14.43%
SRGINFOTEC 0.30 -14.29%
KARMAENG 51.80 -9.44%
BANARBEADS 46.00 -8.46%
ZENITHBIR 0.65 -7.14%
AUSOMENT 33.05 -7.03%
ASIL 0.70 -6.67%
More..

FDC Limited (NSE: FDC)

FDC Technical Analysis 5
As on 9th Dec 2016 FDC Share Price closed @ 223.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 196.15 & Strong Buy for SHORT-TERM with Stoploss of 219.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
FDC Target for December
1st Target up-side 245.06
2nd Target up-side 263.4
3rd Target up-side 281.73
1st Target down-side 192.74
2nd Target down-side 174.4
3rd Target down-side 156.07
FDC Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 56.01 Sideways
MFI (14) MFI is 77.53 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is -21.05 Sideways
ADX (14) ADX is 10.68 Range Bound
PSAR Stoploss For Short Sell 233.95
10 Day Avg Volume Traded 114.59 % More then 10 Day Average Volume
FDC Other Details
Segment EQ
Market Capital 5328551936.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.fdcindia.com
FDC Address
FDC
142-48, S. V. Road
Jogeshwari (West)
Mumbai, 400 102
India
Phone: 91 22 2678 0652
Fax: 91 22 2678 8123
Interactive Technical Analysis Chart FDC Limited ( FDC NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on FDC Limited
FDC Business Profile
FDC, formerly FairDeal Corporation, is engaged in bulk drugs, formulations and food products. It has a presence in numerous therapeutic segments such as anti-infectives, dermatologicals, respiratory, haematinics and ophthalmics. Its plant in Roha manufactures pharma dosage forms, food products and bulk drugs for anti-rheumatic, anti-asthmatics, opthalmic and ENT segments. These bulk drugs are either exported (more than 80% of the production) or formulated at the company`s plants in Jogeshwari and Waluj. FDC, which also manufactures Electral and oral rehydration salts (ORS), has a market share of 1.32%. The company has a manufacturing plant in Goa for manufacture of tablet dosage forms. FDC is in the process of setting up additional facilities to manufacture sterile ophthalmic dosage forms at Waluj by adding one more form-fill-seal (FFS) machine. The said plant has quality systems of international GMP standards, which will enable the company to enter the US generic market and also cater to the expanding domestic demand. FDC`s subsidiaries are FDC Holdings; Netherlands BV; FDC International, UK; and FDC Inc, New Jersey, USA. Fair Deal Corporation Pharmaceutical SA is its joint venture entity. The company is in the process of developing a Concept Product that offers photo-protection in various ocular conditions including dry eyes. It has completed filing of four ANDAs for ophthalmic dosage forms and has plans to file further four ANDAs for molecules going off patentin the near future. The company plans to design and develop economically viable sequences for manufacture of APIs with domestic and export potential. It plans to implement backward integration to create and formulate substitutes for imported raw materials. There is a focus on filing process and product patents along with the development of various sustained release dosage forms and modern/future drug delivery systems. The company also desires to develop new products for the domestic, export markets and also for social causes apart from developing nutraceuticals and extensions to the range of food products. The current market capitalization stands at Rs 1,805.01 crore.The company has reported a standalone sales of Rs 228.72 crore and a Net Profit of Rs 49.07 crore for the quarter ended September 2013. The company management includes Mohan A Chandavarkar - Chairman & Managing Director, Nandan M Chandavarkar - Joint Managing Director, Ashok A Chandavarkar - Director, Ameya A Chandavarkar - Director, Girish C Sharedalal - Director, Satish S Ugrankar - Director, Rahim H Muljiani - Director, Nagam H Atthreya - Director, Vinod G Yennemadi - Director. The Registered office is at B-8, MIDC Industrial Estate, Waluj, Aurangabad District,Maharashtra - 431136 and corporate office is at 142-148, S.V. Road, Jogeshwari (W), Mumbai - 400102.